A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.

Citrin DL, Resnick MI, Guinan P, al-Bussam N, Scott M, Gau TC, Kennealey GT

The Prostate1 Jan 1991Cited by 22 (Europe PMC)

PMID1826048DOI10.1002/pros.2990180206PepBankPUB-01826048

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In stage D2 prostate cancer, objective response occurred in 88% with goserelin and 84% with diethylstilbestrol.
In plain wordsIn prostate cancer patients, response occurred in 88% with goserelin and 84% with diethylstilbestrol.
Peptide
Goserelin
Outcome
Direction not reportedObjective response
Study
n = 67
Comparator
Diethylstilbestrol
Outcome group
Tumor growth · Cancer
Studied dose
3.6 mg every 28 days · subcutaneousAs given in this study (human).
Measurements
Objective response
88%
goserelin
Objective response
84%
diethylstilbestrol
Source sentences
Summary
According to modified criteria of the National Prostatic Cancer Project, 88% of patients in the ZOLADEX group and 84% in the DES group were objective responders.
3 context sentences(design, population, supporting numbers)
Summary · context
This open, prospective study was conducted to compare ZOLADEX (goserelin acetate implant) and diethylstilbestrol (DES) in the treatment of stage D2 prostate cancer.
Summary · context
Sixty-seven patients were allocated to receive 3.6 mg of ZOLADEX every 28 days by subcutaneous injection (n = 48) or 3 mg of DES daily by oral administration (n = 19).
Title · context
A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.
Report a problemFND-0182604802
02HumanRandomized controlled trialEfficacy outcome
In stage D2 prostate cancer, time to treatment failure was not significantly different between goserelin and diethylstilbestrol, although the confidence limits for the hazard ratios were wide.
In plain wordsIn stage D2 prostate cancer, time to treatment failure was not significantly different between goserelin and diethylstilbestrol, though the confidence limits were wide.
Peptide
Goserelin
Outcome
No significant changeTime to treatment failure
Study
n = 67
Comparator
Diethylstilbestrol
Outcome group
Tumor growth · Cancer
Studied dose
3.6 mg every 28 days · subcutaneousAs given in this study (human).
Source sentences
Summary
Time to treatment failure and survival were not significantly different between groups, yet the confidence limits for the hazard ratios were wide.
3 context sentences(design, population, supporting numbers)
Summary · context
This open, prospective study was conducted to compare ZOLADEX (goserelin acetate implant) and diethylstilbestrol (DES) in the treatment of stage D2 prostate cancer.
Summary · context
Sixty-seven patients were allocated to receive 3.6 mg of ZOLADEX every 28 days by subcutaneous injection (n = 48) or 3 mg of DES daily by oral administration (n = 19).
Title · context
A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.
Report a problemFND-0182604803
03HumanRandomized controlled trialEfficacy outcome
In stage D2 prostate cancer, survival was not significantly different between goserelin and diethylstilbestrol, although the confidence limits for the hazard ratios were wide.
In plain wordsIn stage D2 prostate cancer, survival was not significantly different between goserelin and diethylstilbestrol, though the confidence limits were wide.
Peptide
Goserelin
Outcome
No significant changeSurvival
Study
n = 67
Comparator
Diethylstilbestrol
Outcome group
Mortality · Cancer
Studied dose
3.6 mg every 28 days · subcutaneousAs given in this study (human).
Source sentences
Summary
Time to treatment failure and survival were not significantly different between groups, yet the confidence limits for the hazard ratios were wide.
3 context sentences(design, population, supporting numbers)
Summary · context
This open, prospective study was conducted to compare ZOLADEX (goserelin acetate implant) and diethylstilbestrol (DES) in the treatment of stage D2 prostate cancer.
Summary · context
Sixty-seven patients were allocated to receive 3.6 mg of ZOLADEX every 28 days by subcutaneous injection (n = 48) or 3 mg of DES daily by oral administration (n = 19).
Title · context
A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.
Report a problemFND-0182604804
04HumanRandomized controlled trialSafety outcome
In stage D2 prostate cancer, goserelin was better tolerated than diethylstilbestrol.
In plain wordsIn prostate cancer patients, goserelin was better tolerated than diethylstilbestrol.
Peptide
Goserelin
Outcome
Direction not reportedTolerability
Study
n = 67
Comparator
Diethylstilbestrol
Outcome group
Adverse events · Whole body
Studied dose
3.6 mg every 28 days · subcutaneousAs given in this study (human).
Source sentences
Summary
ZOLADEX was better tolerated than DES.
3 context sentences(design, population, supporting numbers)
Summary · context
This open, prospective study was conducted to compare ZOLADEX (goserelin acetate implant) and diethylstilbestrol (DES) in the treatment of stage D2 prostate cancer.
Summary · context
Sixty-seven patients were allocated to receive 3.6 mg of ZOLADEX every 28 days by subcutaneous injection (n = 48) or 3 mg of DES daily by oral administration (n = 19).
Title · context
A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.
Report a problemFND-0182604805
05HumanNon-randomized trialEfficacy outcome
In stage D2 prostate cancer, median testosterone fell below 50 ng/dl within one month in both goserelin and DES groups and remained suppressed up to 120 weeks.
In plain wordsIn prostate cancer patients, goserelin reduced testosterone to castrate levels, as did diethylstilbestrol.
Peptide
Goserelin
Outcome
DecreaseSerum testosterone
Study
n = 67
Comparator
Diethylstilbestrol
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg every 28 days · subcutaneousAs given in this study (human).
Measurements
Testosterone
< 50 ng/dl
castrate levels
Source sentences
Summary
Median serum levels of testosterone were reduced to castrate levels (less than 50 ng/dl) within one month of therapy in each group and remained so for up to 120 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
This open, prospective study was conducted to compare ZOLADEX (goserelin acetate implant) and diethylstilbestrol (DES) in the treatment of stage D2 prostate cancer.
Summary · context
Sixty-seven patients were allocated to receive 3.6 mg of ZOLADEX every 28 days by subcutaneous injection (n = 48) or 3 mg of DES daily by oral administration (n = 19).
Title · context
A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.
Report a problemFND-0182604801

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.